卵巢癌免疫检查点抑制剂应用的现状与挑战  

Immune checkpoint blockades for ovarian cancer:current status and challenges

作　　者：陈雨莲 臧荣余[1] CHEN Yu-lian;ZANG Rong-yu(Institute for Ovarian Cancer,Fudan University&Department of Gynecologic Oncology,Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学卵巢癌研究所,复旦大学附属中山医院妇科肿瘤科,上海200032

出　　处：《中国实用妇科与产科杂志》2024年第11期1078-1082,共5页Chinese Journal of Practical Gynecology and Obstetrics

基　　金：国家自然科学基金面上项目(82473027;82273388);上海市科学技术委员会医学创新研究专项(22Y21900300)。

摘　　要：免疫检查点抑制剂(ICBs)在多个实体瘤治疗中取得突破性进展。但在卵巢癌中,主要是高级别浆液性癌(HGSC),无论是单药还是联合治疗方案,相关临床研究结果均不理想。卵巢癌肿瘤免疫微环境呈现PD-L1表达低、肿瘤突变负荷低、淋巴细胞不同程度浸润、多种免疫抑制细胞共存的高度复杂性和异质性。结合患者的基因组和免疫表型特征,设计合理的临床试验,提高治疗的精准性和有效性,是需要重点关注的方向。Immune checkpoint blockades(ICBs)have achieved breakthrough in the treatment of multiple solid tumors.However,in the treatment of ovarian cancer,mainly high grade serous tubo-ovarian cancer(HGSC),neither single agent of ICBs nor ICB-based combination therapies have shown good results in clinical researches.The tumor immune microenvironment of ovarian cancer is highly complex and heterogenous,with low PD-L1 expression,low tumor mutation burden,different phenotypes of lymphocytes infiltration in tumors,and presence of multiple immunosuppressive cells.We still need well-designed clinical trials considering the patients'genomic and immune phenotypes to improve the accuracy and effectiveness of treatment.

关 键 词：卵巢癌 免疫检查点抑制剂 肿瘤免疫微环境 

分 类 号：R737.31[医药卫生—肿瘤]